"In 2023, our unique position in the immune-oncology field has been strengthened with positive interim results from two phase II studies. Our oncolytic molecules have the potential to solve one of the major challenges in current cancer therapy: tumor heterogeneity", says Øystein Rekdal, CEO of
The Annual Report for 2023 is attached to this notice and is also available on the company's website, www.lytixbiopharma.com, under Investors.
For further information, please see the Company's website or contact CFO Gjest Breistein. Please see below for contact details.
Gjest Breistein, CFO
E-mail: gjest.breistein@lytixbiopharma.com
Phone: +47 952 60 512
About Lytix
Based in
https://news.cision.com/lytix-biopharma-as/r/lytix-biopharma-as--annual-report-for-2023,c3970397
https://mb.cision.com/Main/16482/3970397/2769254.pdf
https://mb.cision.com/Public/16482/3970397/8b230c2c1eb02ee2.pdf
(c) 2024 Cision. All rights reserved., source